No, it is not something you have to simply accept.
In a large trial population of women with moderate-to-severe vulvovaginal symptoms, pain with vaginal penetration was the single most bothersome symptom for 60% of women, well ahead of dryness at 21%, making painful sex the leading edge of GSM rather than a minor footnote. Low-dose vaginal estrogen has the most robust evidence base of any GSM treatment, though one major trial found a low-dose vaginal tablet no better than a lubricating placebo gel at 12 weeks on symptom scores alone, even as objective measures like vaginal pH and tissue changes clearly favored estrogen. Where pain has led to muscle guarding, pelvic floor physical therapy addressing the muscular component alongside local hormones is a recognized combined approach. If pain is severe, some clinicians report added benefit from switching to vaginal DHEA, which contains an androgen component that estrogen alone does not.
The disagreement is not about whether painful sex should be treated, but about how much credit low-dose vaginal estrogen deserves for symptom relief specifically, after a well-designed trial found it no better than a lubricating placebo gel at 12 weeks on symptom scores.
What the research shows, and which source each finding rests on
In a trial population of women with moderate-to-severe vulvovaginal symptoms, pain with vaginal penetration was the most bothersome symptom for 60%, versus 21% for dryness.
In the REVIVE survey of 3,046 women, dyspareunia (painful sex) was reported by 44%, and symptoms affected enjoyment of sex in 59%.
The 2025 AUA/SUFU/AUGS guideline states that among all hormonal and non-hormonal GSM options, local low-dose vaginal estrogen has the most robust evidence base.
Pelvic floor physical therapy has Cochrane-grade evidence for urinary incontinence (about 8 times more likely to report cure than controls) and is used alongside local hormones for the muscular component of pain with sex, though this specific combination is supported by expert practice standard rather than large randomized trials.
Where the real disagreement is
Each position is shown with its own sources. A position listed here is not necessarily the accepted view.
Modest symptom benefit; moisturizers are reasonable first-line for mild cases
Evidence-conservative reading of the trial data, aligned with NAMS 2020
The 12-week trial found no advantage of a low-dose tablet over a placebo gel that was itself moisturizing, so for mild dryness alone a good moisturizer may do just as well.
Symptom scores understate the real tissue effect
Sexual-medicine field reading, Rachel Rubin and Kelly Casperson
The placebo gel was a lubricating treatment, not an inert control, and the objective endpoints, vaginal pH, tissue maturation and UTI reduction, clearly favor estrogen; a therapy's full tissue effect and its biggest payoff, UTI prevention, are not captured by a 12-week symptom score.
What would settle it: Head-to-head trials measuring both symptom scores and objective tissue or infection endpoints over 6 to 12 months would clarify how much of the benefit shows up on symptom scales versus tissue biology.
What is really going on here
- Which formulation fits my life - cream, insert, ring or DHEA?
- Before pursuing a desire treatment, has anyone assessed whether sex actually hurts?
Questions for your doctor
- Is my pain likely tissue-related, muscle-related, or both?
- Should we try local vaginal hormones, pelvic floor physical therapy, or both together?
- If the first product I try doesn't work well for me, can we switch rather than give up?
- Would vaginal DHEA be worth trying if estrogen alone doesn't fully resolve the pain?
Questions with no answer yet
In the trial that found a low-dose vaginal tablet no better than a lubricating placebo gel at 12 weeks on symptom scores, would a longer treatment period of 6 to 12 months, allowing for the tissue's full remodeling time, have shown a bigger gap between the two, given that the objective tissue measures favored estrogen even when symptom scores did not?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: Head-to-head trials measuring both symptom scores and objective tissue or infection endpoints over 6 to 12 months are described as what would clarify this, and this combination has not been tested. The existing trial measured only a 12-week window.
What would test it: The longer-duration, dual-endpoint trial described above.
For women whose pain persists despite adequate local hormone treatment, does adding vaginal DHEA specifically for its androgen component produce a measurably different result than switching to a different estrogen formulation, or is any product switch equally likely to help?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: Clinical reports describe switching women who still have pain on vaginal estrogen to vaginal DHEA and observing improvement attributed to the androgen component, explicitly framed as clinical experience and mechanistic reasoning rather than head-to-head trial data.
What would test it: A randomized trial comparing a switch to vaginal DHEA against a switch to a different estrogen formulation, in women with inadequate response to their first local hormone product.
Does starting pelvic floor physical therapy at the same time as local hormone treatment, rather than after hormone treatment alone has been tried, produce faster or more complete pain relief for the muscular component of painful sex?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: The combined tissue-plus-muscle model is described as an expert practice standard rather than something tested in a large randomized trial comparing simultaneous versus sequential treatment order.
What would test it: A randomized trial comparing simultaneous initiation of local hormones and pelvic floor physical therapy against sequential initiation, with hormones first and therapy added later if pain persists.
Sources
- 1.Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms: A Randomized Clinical Trial.Mitchell CM, et al. Efficacy of Vaginal Estradiol or Vaginal Moisturizer vs Placebo for Treating Postmenopausal Vulvovaginal Symptoms (MsFLASH). JAMA Intern Med 2018;178(5):681-690 · Randomised trial
- 2.Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women's VIews of Treatment Options for Menopausal Vaginal ChangEs) survey.Kingsberg SA, et al. REVIVE survey. J Sex Med 2013;10(7):1790-9 · Observational study
- 3.The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause.AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause, J Urol 2025;214(3):242-250 · Systematic review or guideline
- 4.Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women.Dumoulin C, et al. Pelvic floor muscle training versus no treatment for urinary incontinence in women. Cochrane Database Syst Rev 2018;10:CD005654 · Systematic review or guideline
The letter grades the type of study behind a claim, not the answer itself.
This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.
You are not imagining it
In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.
Start Free MappingRelated questions
- What is GSM (genitourinary syndrome of menopause) and why does it affect both my vagina and my bladder?
- Is vaginal estrogen safe, and what happened to that scary warning label about stroke and cancer?
- Can I use vaginal estrogen if I've had breast cancer?
- I keep getting UTIs after menopause and keep getting put on antibiotics - can vaginal estrogen actually help?
- What is vaginal DHEA (prasterone) and how is it different from vaginal estrogen?
- What is ospemifene, the daily pill for painful sex, and how does it work?
- Back to topic: Vaginal, sexual and urinary health